Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LLPH divergent transcript (LLPH-DT) is an antisense long noncoding RNA gene located adjacent to the LLPH protein-coding gene in a head-to-head orientation, producing a transcript that runs antisense to LLPH mRNA. Like other divergent antisense transcripts, LLPH-DT may regulate the expression of its neighboring gene (LLPH) and participate in broader epigenetic and transcriptional processes. Antisense RNAs frequently influence gene activity by modulating chromatin, transcription initiation, and interfering with mRNA stability. While the specific biological and disease roles of LLPH-DT remain poorly characterized, the family of antisense long noncoding RNAs is increasingly recognized for its potential impacts on cellular regulation, imprinting, and disease susceptibility. No drugs or clinical biomarkers are currently associated with LLPH-DT, and it is not presently considered a canonical therapeutic target.
Not directly applicable; as a lncRNA, possible mechanisms include modulation of chromatin state, transcriptional interference, and recruitment of epigenetic regulators to the LLPH locus or its neighboring genes
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LLPH divergent transcript (LLPH-DT).